<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985673</url>
  </required_header>
  <id_info>
    <org_study_id>113536</org_study_id>
    <nct_id>NCT00985673</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults</brief_title>
  <official_title>A Study to Evaluate the Safety and Immunogenicity of an A/California/7/2009 (H1N1)V-like Vaccine GSK2340274A or GSK2340273A Co-administered With Trivalent Inactivated Seasonal Influenza Vaccine in Adults 19 to 40 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety and immunogenicity of the H1N1
      (swine) flu vaccines GSK2340274A and GSK2340273A when co-administered with the seasonal flu
      vaccine in adults 19 to 40 years of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Collaborators: United States Department of Health and Human Services, Office of Biomedical
      Advanced Research and Development Authority
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.</measure>
    <time_frame>21 days after the second dose of Arepanrix vaccine (at Day 42).</time_frame>
    <description>The A/California vaccine virus-homologous antibody response was measured in subjects having received Flulaval vaccine co-administered with the first dose of Arepanrix vaccine, and in subjects having received two doses of Arepanrix vaccine alone.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.</measure>
    <time_frame>21 days after the second dose of the unadjuvanted formulation of Arepanrix vaccine (at Day 42)</time_frame>
    <description>The A/California vaccine virus-homologous antibody response was measured in subjects having received Flulaval vaccine co-administered with the first dose of the unadjuvanted formulation of Arepanrix vaccine, and in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine alone.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).</measure>
    <time_frame>On Days 0, 7, 21, 28, 42, 63 and 182</time_frame>
    <description>Influenza-specific CD4 T-Cells were stimulated in vitro with A/California virus and seasonal Influenza viruses, related antigens or derived peptides.
Stimulating antigens were A/Brisbane, A/California, pool peptides H1N1 and pool FLU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).</measure>
    <time_frame>On Days 0, 7, 21, 28, 42, 63 and 182</time_frame>
    <description>Influenza-specific CD8 T-Cells were stimulated in vitro with A/California virus and seasonal Influenza viruses, related antigens or derived peptides.
Stimulating antigens were A/Brisbane, A/California, pool peptides H1N1 and pool FLU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed</measure>
    <time_frame>On Days 0, 7, 21, 28, 42, 63 and 182</time_frame>
    <description>Laboratory parameters assessed were alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (AP), bilirubin (BIL) (total (T)), basophils (BAS). For each parameter and for each range it was assessed whether the values of the subjects were in unkown, above, below or within the range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed</measure>
    <time_frame>On Days 0, 7, 21, 28, 42, 63 and 182</time_frame>
    <description>Laboratory parameters assessed were creatinine (CREA), bilirubin (BIL) (direct (D)), eosinophils (EOS), hemoglobin (Hgb), hematocrit (Hct). For each parameter and for each range it was assessed whether the values of the subjects were unknown, in above, below or within the range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local Symptoms.</measure>
    <time_frame>During a 7-day follow-up period (Days 0-6) post-vaccination period</time_frame>
    <description>Solicited local symptoms assessed were pain, redness and swelling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited General Symptoms.</measure>
    <time_frame>During a 7-day follow-up period (Days 0-6) post-vaccination period</time_frame>
    <description>Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature. Temperature is defined as an axillary temperature equal to or above 38.0 degrees Celsius (°C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed</measure>
    <time_frame>On Days 0, 7, 21, 28, 42, 63 and 182</time_frame>
    <description>Laboratory parameters assessed were serum urea nitrogen (SUN), white blood cells (WBC), red blood cells (RBC). For each parameter and for each range it was assessed whether the values of the subjects were unknown, above, below or within the range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AEs).</measure>
    <time_frame>Within the 84-day (Days 0-83) post-vaccination period.</time_frame>
    <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Medically Attended Visits (MAEs).</measure>
    <time_frame>During the entire study period (Days 0-368).</time_frame>
    <description>The day 368 was the last contact day for the last subject reporting the event. For each solicited and unsolicited symptom the subject experienced, the subject was asked if they received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Potential Immune Diseases (pIMDs).</measure>
    <time_frame>During the entire study period (Days 0-406).</time_frame>
    <description>The day 406 was the last contact day with the subjects reporting the event. Potential immune-mediated diseases (pIMDs) are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs).</measure>
    <time_frame>During the entire study period (Days 0-329).</time_frame>
    <description>The day 329 was the last contact day with the subjects reporting serious adverse events.
SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed</measure>
    <time_frame>On Days 0, 7, 21, 28, 42, 63 and 182</time_frame>
    <description>Laboratory parameters assessed were neutrophils (NEU), lymphocytes (LYM), monocytes (MON) and platelets (PLA). For each parameter and for each range it was assessed whether the values of the subjects were unknown, in above, below or within the range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microneutralization Antibody Titers Against A/California/7/2009 (H1N1) Strain.</measure>
    <time_frame>On Days 0, 21, 42, 63 and 182</time_frame>
    <description>Titers were expressed as geometric mean titers (GMTs) and measured by microneutralization.
Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1).
Microneutralization testing was cancelled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Microneutralization Titer Greater Than or Equal to 1:28 for Antibodies Against A/California/7/2009 (H1N1) Strain.</measure>
    <time_frame>On Days 0, 21, 42, 63 and 182</time_frame>
    <description>Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1).
The antibody cut-off value assessed was a titer of 1:10 and this value was considered as seropositivity.
Seronegative subject is a subject whose antibody titer is below the cut-off value, a seropositive subject is a subject whose antibody titer is greater than or equal to the cut-off value. Microneutralization titers &lt; 1:28 were considered below the cut-off.
Microneutralization testing was cancelled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Response Rates (VRR) for Microneutralization Antibody Titers Against A/California/7/2009 (H1N1) Strain.</measure>
    <time_frame>On Days 0, 21, 42, 63 and 182</time_frame>
    <description>Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1).
Vaccine Response Rate for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0.
Microneutralization testing was cancelled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.</measure>
    <time_frame>21 days after the second dose of Arepanrix vaccine (Day 63 for Flulaval/placebo/Arepanrix Group and Day 42 for Arepanrix/placebo/Flulaval Group)</time_frame>
    <description>The A/California vaccine virus-homologous antibody response was measured in subjects having received two doses of Arepanrix vaccine, with prior treatment with Flulaval vaccine 21 days before the first dose and in subjects having received two doses of Arepanrix vaccine alone.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.</measure>
    <time_frame>21 days after the second dose of the unadjuvanted formulation of Arepanrix vaccine (Day 63 for Flulaval/placebo/unadjuvanted Arepanrix Group and Day 42 for Unadjuvanted Arepanrix/placebo/Flulaval Group)</time_frame>
    <description>The A/California vaccine virus-homologous antibody response was measured in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine, with prior treatment with Flulaval vaccine 21 days before the first dose and in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine alone.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.</measure>
    <time_frame>21 days after the second dose of the pandemic vaccine (at Day 63)</time_frame>
    <description>The A/California vaccine virus-homologous antibody response was measured in subjects pre-treated with Flulaval who subsequently received two doses of the unadjuvanted formulation of Arepanrix vaccine compared to subjects pre-treated with Flulaval vaccine who subsequently received two doses of Arepanrix vaccine.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.</measure>
    <time_frame>21 days after the Flulaval vaccination (at Day 21).</time_frame>
    <description>The antibody response against each of the three Flulaval vaccine components in subjects exposed to co-administration of Flulaval vaccine with the first of two doses of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.
Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.</measure>
    <time_frame>21 days after the Flulaval vaccination (at Day 21).</time_frame>
    <description>The antibody response against each of the three Flulaval vaccine components in subjects exposed to co-administration of Flulaval vaccine with the first of two doses of the unadjuvanted formulation of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.
Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.</measure>
    <time_frame>21 days after the Flulaval vaccination (Day 63 for Arepanrix/placebo/Flulaval Group and Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups)</time_frame>
    <description>The antibody response against each of the three Flulaval vaccine components in subjects exposed to pre-treatment with two doses of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.
Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.</measure>
    <time_frame>21 days after the Flulaval vaccination (Day 63 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups)</time_frame>
    <description>The antibody response against each of the three Flulaval vaccine components in subjects exposed to pre-treatment with two doses of the unadjuvanted formulation of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.
Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.</measure>
    <time_frame>On Days 0, 21, 42 and 63</time_frame>
    <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.</measure>
    <time_frame>At Day 182</time_frame>
    <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects for Antibodies Against A/ California Strain.</measure>
    <time_frame>At Day 63 from Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups; At Day 42 from Day 0 for the 4 other groups</time_frame>
    <description>Seroconversion rate was defined as the incidence rate of vaccinees who had either a pre-vaccination titer recorded as &lt; 1:10 and a post-vaccination reciprocal titer ≥ 40 or a pre-vaccination reciprocal titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer.
Seroconversion defined as:
For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects for Antibodies Against A/California Strain.</measure>
    <time_frame>At Day 63 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups; At Day 42 for the 4 other groups.</time_frame>
    <description>Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Antibodies Against A/California Strain.</measure>
    <time_frame>At Day 63 from Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups; At Day 42 from Day 0 for the 4 other groups</time_frame>
    <description>Seroconversion factor was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the prevaccination reciprocal HI titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.</measure>
    <time_frame>At Day 21 from Day 0 for the pooled group, Flulaval/unadjuvanted Arepanrix/placebo and Flulaval/Arepanrix/placebo Groups; at Day 63 from Day 42 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Arepanrix/placebo/Flulaval Group</time_frame>
    <description>Seroconversion defined as:
For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.
For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains</measure>
    <time_frame>At Day 21 for the pooled group, Flulaval/unadjuvanted Arepanrix/placebo and Flulaval/Arepanrix/placebo Groups; at Day 63 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Arepanrix/placebo/Flulaval Group</time_frame>
    <description>Seroprotection was defined as the proportion of subjects with H1N1 reciprocal Hemagglutination Inhibition (HI) titers ≥ 1:40 against the tested vaccine virus.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.
For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.</measure>
    <time_frame>At Day 21 from Day 0 for the pooled group, Flulaval/unadjuvanted Arepanrix/placebo and Flulaval/Arepanrix/placebo Groups; at Day 63 from Day 42 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Arepanrix/placebo/Flulaval Group</time_frame>
    <description>Seroconversion factor was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal Hemagglutination Inhibition (HI) titer to the prevaccination reciprocal HI titer.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.
For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains</measure>
    <time_frame>on Days 21 and 63 from Day 0 for the first 4 groups; on Days 42 and 63 from Day 0 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups</time_frame>
    <description>Seroconversion defined as:
For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains</measure>
    <time_frame>At Day 182 from Day 0</time_frame>
    <description>Seroconversion defined as:
For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.</measure>
    <time_frame>before vaccination and on days 21 and 63 for the first 4 groups and before vaccination and on days 42 and 63 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups</time_frame>
    <description>Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.</measure>
    <time_frame>At Day 182 after the first dose</time_frame>
    <description>Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.</measure>
    <time_frame>On Days 21 and 63 from Day 0 for the first 4 groups and on Days 42 and 63 from Day 0 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups</time_frame>
    <description>Seroconversion factor of the within-subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.</measure>
    <time_frame>At Day 182 from Day 0</time_frame>
    <description>Seroconversion factor of the within-subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.</measure>
    <time_frame>On Days 0, 21 and 63 for the first 4 groups and on Days 0, 42 and 63 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups</time_frame>
    <description>Titers were expressed as geometric mean titers (GMTs).
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.</measure>
    <time_frame>At Day 182 after dose 1 vaccination</time_frame>
    <description>Titers were expressed as geometric mean titers (GMTs).
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">611</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Flulaval/placebo/unadjuvanted Arepanrix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flulaval/placebo/Arepanrix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flulaval/unadjuvanted Arepanrix/placebo Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flulaval/Arepanrix/placebo Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unadjuvanted Arepanrix/placebo/Flulaval Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arepanrix/placebo/Flulaval Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK2340274A</intervention_name>
    <description>Two intramuscular injections</description>
    <arm_group_label>Arepanrix/placebo/Flulaval Group</arm_group_label>
    <arm_group_label>Flulaval/placebo/Arepanrix Group</arm_group_label>
    <arm_group_label>Flulaval/Arepanrix/placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK2340273A</intervention_name>
    <description>Two intramuscular injections</description>
    <arm_group_label>Flulaval/placebo/unadjuvanted Arepanrix Group</arm_group_label>
    <arm_group_label>Unadjuvanted Arepanrix/placebo/Flulaval Group</arm_group_label>
    <arm_group_label>Flulaval/unadjuvanted Arepanrix/placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal trivalent influenza vaccine (TIV)</intervention_name>
    <description>Single intramuscular injection</description>
    <arm_group_label>Arepanrix/placebo/Flulaval Group</arm_group_label>
    <arm_group_label>Flulaval/placebo/unadjuvanted Arepanrix Group</arm_group_label>
    <arm_group_label>Flulaval/placebo/Arepanrix Group</arm_group_label>
    <arm_group_label>Unadjuvanted Arepanrix/placebo/Flulaval Group</arm_group_label>
    <arm_group_label>Flulaval/Arepanrix/placebo Group</arm_group_label>
    <arm_group_label>Flulaval/unadjuvanted Arepanrix/placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>Single intramuscular injection</description>
    <arm_group_label>Arepanrix/placebo/Flulaval Group</arm_group_label>
    <arm_group_label>Flulaval/placebo/unadjuvanted Arepanrix Group</arm_group_label>
    <arm_group_label>Flulaval/placebo/Arepanrix Group</arm_group_label>
    <arm_group_label>Unadjuvanted Arepanrix/placebo/Flulaval Group</arm_group_label>
    <arm_group_label>Flulaval/Arepanrix/placebo Group</arm_group_label>
    <arm_group_label>Flulaval/unadjuvanted Arepanrix/placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol.

          -  Written informed consent obtained from the subject.

          -  Male or female adults, 19-40 years of age at the time of the first vaccination.

          -  Safety laboratory tests results within the parameters specified in the protocol.

          -  Satisfactory baseline medical assessment by physical examination.

          -  Comprehension of the study requirements, ability to comprehend and comply with
             procedures for collection of safety data, expressed availability for the required
             study period, and ability and willingness to attend scheduled visits as documented by
             signature on the informed consent document.

          -  Access to a consistent means of telephone contact, which may be either in the home or
             at the workplace, land line, or mobile, but NOT a pay phone or other multiple-user
             device.

          -  Female subjects of non-childbearing potential may be enrolled in the study.

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

          -  has practiced adequate contraception for 30 days prior to vaccination, and

          -  has a negative pregnancy test on the day of first vaccination, and

          -  has agreed to continue adequate contraception during the entire treatment period and
             for 2 months after completion of the vaccination series.

        Exclusion Criteria:

          -  Previous vaccination with an H1N1v-like virus vaccine or a medical history of
             physician-confirmed infection with an H1N1v-like virus.

          -  Prior receipt at any time of any seasonal influenza vaccine.

          -  Planned administration of any vaccine not foreseen by the study protocol between Day 0
             and the Day 63 phlebotomy.

          -  Administration of any licensed vaccine within 4 weeks before the first study vaccine
             dose.

          -  Use of any investigational or non-registered product other than the study vaccines
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period.

          -  Receipt of systemic glucocorticoids within one month prior to study enrolment, or any
             other cytotoxic or immunosuppressive drug within six months of study enrolment.
             Topical, intra-articularly injected, or inhaled glucocorticoids, topical calcineurin
             inhibitors or imiquimod are allowed.

          -  Receipt of any immunoglobulins and/or any blood products within three months of study
             enrolment or planned administration of any of these products during the study period.

          -  Presence of evidence of substance abuse or of neurological or psychiatric diagnoses
             which, even if stable, are deemed by the investigator to render the potential subject
             unable/unlikely to provide accurate safety reports.

          -  Presence of a temperature &gt;= 38.0ºC (&gt;=100.4ºF), or acute symptoms greater than &quot;mild&quot;
             severity on the scheduled date of first vaccination.

          -  Diagnosed with cancer, or treatment for cancer, within 3 years.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  Any significant disorder of coagulation or treatment with warfarin derivatives or
             heparin. Persons receiving individual doses of low molecular weight heparin outside of
             24 hours prior to vaccination are eligible. Persons receiving prophylactic
             antiplatelet medications, e.g., low-dose acetylsalicylic acid, and without a
             clinically-apparent bleeding tendency, are eligible.

          -  An acute evolving neurological disorder or history of Guillain-Barré syndrome within
             six weeks of receipt of seasonal influenza vaccine.

          -  Any known or suspected allergy to any constituent of influenza vaccines; a history of
             anaphylactic-type reaction to any constituent of influenza vaccines; or a history of
             severe adverse reaction to a previous influenza vaccine.

          -  Known pregnancy or a positive urine beta-human chorionic gonadotropin test result
             prior to first vaccination.

          -  Lactating or nursing women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 4J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2009</study_first_posted>
  <results_first_submitted>December 21, 2011</results_first_submitted>
  <results_first_submitted_qc>December 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2012</results_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK Bio's influenza vaccine GSK2340274A</keyword>
  <keyword>influenza infection</keyword>
  <keyword>GSK Bio's influenza vaccine GSK2340273A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113536</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113536</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113536</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113536</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113536</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113536</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113536</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
          <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>Flulaval/Placebo/Arepanrix Group</title>
          <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="P3">
          <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
          <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="P4">
          <title>Flulaval/Arepanrix/Placebo Group</title>
          <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="P5">
          <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
          <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="P6">
          <title>Arepanrix/Placebo/Flulaval Group</title>
          <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="102"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="101"/>
                <participants group_id="P6" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="90"/>
                <participants group_id="P4" count="88"/>
                <participants group_id="P5" count="93"/>
                <participants group_id="P6" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
          <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="B2">
          <title>Flulaval/Placebo/Arepanrix Group</title>
          <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
          <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>Flulaval/Arepanrix/Placebo Group</title>
          <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="B5">
          <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
          <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="B6">
          <title>Arepanrix/Placebo/Flulaval Group</title>
          <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="102"/>
            <count group_id="B4" value="100"/>
            <count group_id="B5" value="101"/>
            <count group_id="B6" value="102"/>
            <count group_id="B7" value="611"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.7" spread="6.20"/>
                    <measurement group_id="B2" value="28.6" spread="6.24"/>
                    <measurement group_id="B3" value="28.2" spread="6.32"/>
                    <measurement group_id="B4" value="29.2" spread="6.12"/>
                    <measurement group_id="B5" value="29.3" spread="6.47"/>
                    <measurement group_id="B6" value="28.1" spread="6.08"/>
                    <measurement group_id="B7" value="28.9" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="60"/>
                    <measurement group_id="B6" value="58"/>
                    <measurement group_id="B7" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="44"/>
                    <measurement group_id="B7" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).</title>
        <description>Influenza-specific CD4 T-Cells were stimulated in vitro with A/California virus and seasonal Influenza viruses, related antigens or derived peptides.
Stimulating antigens were A/Brisbane, A/California, pool peptides H1N1 and pool FLU.</description>
        <time_frame>On Days 0, 7, 21, 28, 42, 63 and 182</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at day 182.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).</title>
          <description>Influenza-specific CD4 T-Cells were stimulated in vitro with A/California virus and seasonal Influenza viruses, related antigens or derived peptides.
Stimulating antigens were A/Brisbane, A/California, pool peptides H1N1 and pool FLU.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at day 182.</population>
          <units>Number of T cells/million</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane [D0] (N=25,25,24,25,25,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2533.40" spread="1225.90"/>
                    <measurement group_id="O2" value="2604.64" spread="1435.48"/>
                    <measurement group_id="O3" value="3521.33" spread="1922.24"/>
                    <measurement group_id="O4" value="2612.56" spread="1256.47"/>
                    <measurement group_id="O5" value="2644.40" spread="1219.04"/>
                    <measurement group_id="O6" value="2016.31" spread="822.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [D7] (N=24,27,24,23,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4437.33" spread="1930.30"/>
                    <measurement group_id="O2" value="4595.26" spread="2058.76"/>
                    <measurement group_id="O3" value="5560.33" spread="3301.90"/>
                    <measurement group_id="O4" value="6242.30" spread="2773.60"/>
                    <measurement group_id="O5" value="4269.96" spread="1744.37"/>
                    <measurement group_id="O6" value="4674.88" spread="2325.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [D21] (N=26,25,27,24,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3561.00" spread="1502.24"/>
                    <measurement group_id="O2" value="3756.72" spread="1379.69"/>
                    <measurement group_id="O3" value="5581.78" spread="3123.38"/>
                    <measurement group_id="O4" value="6069.67" spread="3306.79"/>
                    <measurement group_id="O5" value="3894.54" spread="1596.44"/>
                    <measurement group_id="O6" value="5590.23" spread="2407.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [D28] (N=27,27,27,26,25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3500.22" spread="1615.89"/>
                    <measurement group_id="O2" value="4269.11" spread="1482.01"/>
                    <measurement group_id="O3" value="5102.78" spread="2856.77"/>
                    <measurement group_id="O4" value="6989.15" spread="3950.45"/>
                    <measurement group_id="O5" value="3816.20" spread="1290.25"/>
                    <measurement group_id="O6" value="7083.19" spread="3227.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [D42] (N=27,26,27,27,24,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3595.11" spread="1268.17"/>
                    <measurement group_id="O2" value="5246.88" spread="2407.94"/>
                    <measurement group_id="O3" value="4791.41" spread="2706.43"/>
                    <measurement group_id="O4" value="5607.96" spread="2773.17"/>
                    <measurement group_id="O5" value="3872.67" spread="1270.26"/>
                    <measurement group_id="O6" value="6200.64" spread="2733.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [D63] (N=26,26,25,25,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3407.62" spread="1114.62"/>
                    <measurement group_id="O2" value="6444.50" spread="2681.50"/>
                    <measurement group_id="O3" value="4169.32" spread="2216.49"/>
                    <measurement group_id="O4" value="5020.88" spread="2346.39"/>
                    <measurement group_id="O5" value="4074.38" spread="1639.45"/>
                    <measurement group_id="O6" value="5757.04" spread="3131.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [D182] (N=26,24,26,26,25,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3190.31" spread="1086.38"/>
                    <measurement group_id="O2" value="4631.00" spread="1834.57"/>
                    <measurement group_id="O3" value="4132.81" spread="1816.70"/>
                    <measurement group_id="O4" value="3988.04" spread="1606.16"/>
                    <measurement group_id="O5" value="3672.16" spread="1191.85"/>
                    <measurement group_id="O6" value="4568.16" spread="2043.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California [D0] (N=25,25,24,25,25,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2176.28" spread="1226.08"/>
                    <measurement group_id="O2" value="1988.24" spread="1072.73"/>
                    <measurement group_id="O3" value="2804.63" spread="1912.94"/>
                    <measurement group_id="O4" value="2055.44" spread="1053.95"/>
                    <measurement group_id="O5" value="2109.52" spread="828.11"/>
                    <measurement group_id="O6" value="1641.04" spread="799.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California [D7] (N=24,27,24,23,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4089.25" spread="2131.69"/>
                    <measurement group_id="O2" value="3852.44" spread="1970.35"/>
                    <measurement group_id="O3" value="4780.21" spread="2828.25"/>
                    <measurement group_id="O4" value="5265.74" spread="2008.41"/>
                    <measurement group_id="O5" value="3224.42" spread="1238.08"/>
                    <measurement group_id="O6" value="3590.08" spread="1912.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California [D21] (N=26,25,27,24,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3144.62" spread="1723.51"/>
                    <measurement group_id="O2" value="3032.52" spread="1342.30"/>
                    <measurement group_id="O3" value="4455.00" spread="2768.12"/>
                    <measurement group_id="O4" value="4986.71" spread="2398.42"/>
                    <measurement group_id="O5" value="2975.38" spread="1058.31"/>
                    <measurement group_id="O6" value="4793.35" spread="2194.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California [D28] (N=27,27,27,26,25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3061.63" spread="1632.58"/>
                    <measurement group_id="O2" value="3770.44" spread="1460.62"/>
                    <measurement group_id="O3" value="4058.63" spread="2349.19"/>
                    <measurement group_id="O4" value="5979.12" spread="3448.84"/>
                    <measurement group_id="O5" value="2875.52" spread="837.73"/>
                    <measurement group_id="O6" value="6689.44" spread="3501.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California [D42] (N=27,27,27,27,24,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2931.04" spread="1276.42"/>
                    <measurement group_id="O2" value="4381.48" spread="2053.51"/>
                    <measurement group_id="O3" value="3720.07" spread="2261.08"/>
                    <measurement group_id="O4" value="4658.07" spread="1939.82"/>
                    <measurement group_id="O5" value="2838.00" spread="1008.20"/>
                    <measurement group_id="O6" value="5622.14" spread="2870.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California [D63] (N=26,26,25,25,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2768.15" spread="1109.96"/>
                    <measurement group_id="O2" value="5328.19" spread="2436.59"/>
                    <measurement group_id="O3" value="3149.00" spread="1844.25"/>
                    <measurement group_id="O4" value="3967.12" spread="1655.09"/>
                    <measurement group_id="O5" value="3246.71" spread="1379.49"/>
                    <measurement group_id="O6" value="5151.62" spread="3008.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California [D182] (N=26,24,26,26,25,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1461.88" spread="735.77"/>
                    <measurement group_id="O2" value="2333.88" spread="925.38"/>
                    <measurement group_id="O3" value="1838.96" spread="842.26"/>
                    <measurement group_id="O4" value="2068.73" spread="939.92"/>
                    <measurement group_id="O5" value="1630.40" spread="592.23"/>
                    <measurement group_id="O6" value="2513.48" spread="1232.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool peptides H1 [D0] (N=25,24,24,25,23,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349.64" spread="336.13"/>
                    <measurement group_id="O2" value="428.00" spread="296.76"/>
                    <measurement group_id="O3" value="356.79" spread="206.44"/>
                    <measurement group_id="O4" value="320.52" spread="216.19"/>
                    <measurement group_id="O5" value="443.35" spread="356.02"/>
                    <measurement group_id="O6" value="271.76" spread="180.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool peptides H1 [D7] (N=24,27,24,23,24,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="596.42" spread="500.15"/>
                    <measurement group_id="O2" value="581.63" spread="527.07"/>
                    <measurement group_id="O3" value="708.96" spread="518.87"/>
                    <measurement group_id="O4" value="857.04" spread="474.48"/>
                    <measurement group_id="O5" value="692.29" spread="454.48"/>
                    <measurement group_id="O6" value="718.76" spread="663.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool peptides H1 [D21] (N=26,24,27,24,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="465.42" spread="352.18"/>
                    <measurement group_id="O2" value="589.79" spread="459.57"/>
                    <measurement group_id="O3" value="728.15" spread="623.89"/>
                    <measurement group_id="O4" value="974.67" spread="579.23"/>
                    <measurement group_id="O5" value="619.50" spread="391.47"/>
                    <measurement group_id="O6" value="1022.38" spread="572.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool peptides H1 [D28] (N=26,27,27,26,25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="480.42" spread="392.81"/>
                    <measurement group_id="O2" value="704.59" spread="518.63"/>
                    <measurement group_id="O3" value="528.78" spread="322.10"/>
                    <measurement group_id="O4" value="1345.69" spread="1536.94"/>
                    <measurement group_id="O5" value="642.00" spread="379.90"/>
                    <measurement group_id="O6" value="1251.07" spread="695.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool peptides H1 [D42] (N=27,27,27,27,24,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="467.70" spread="302.91"/>
                    <measurement group_id="O2" value="1049.96" spread="865.58"/>
                    <measurement group_id="O3" value="514.78" spread="296.67"/>
                    <measurement group_id="O4" value="1080.93" spread="669.26"/>
                    <measurement group_id="O5" value="600.04" spread="496.71"/>
                    <measurement group_id="O6" value="1228.25" spread="637.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool peptides H1 [D63] (N=26,26,25,25,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="504.92" spread="321.17"/>
                    <measurement group_id="O2" value="1248.54" spread="1175.35"/>
                    <measurement group_id="O3" value="460.28" spread="267.85"/>
                    <measurement group_id="O4" value="815.24" spread="634.45"/>
                    <measurement group_id="O5" value="508.58" spread="316.75"/>
                    <measurement group_id="O6" value="910.81" spread="482.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool peptides H1 [D182] (N=26,24,26,26,25,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="554.65" spread="439.30"/>
                    <measurement group_id="O2" value="824.17" spread="565.53"/>
                    <measurement group_id="O3" value="531.73" spread="481.91"/>
                    <measurement group_id="O4" value="648.69" spread="557.34"/>
                    <measurement group_id="O5" value="552.52" spread="528.46"/>
                    <measurement group_id="O6" value="757.68" spread="638.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool Flu [D0] (N=24,25,24,25,25,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3286.63" spread="1710.00"/>
                    <measurement group_id="O2" value="3531.36" spread="1972.37"/>
                    <measurement group_id="O3" value="4315.71" spread="2499.77"/>
                    <measurement group_id="O4" value="3056.80" spread="1096.38"/>
                    <measurement group_id="O5" value="3308.08" spread="1124.49"/>
                    <measurement group_id="O6" value="2775.50" spread="1214.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool Flu [D7] (N=24,27,24,23,24,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6574.50" spread="3399.35"/>
                    <measurement group_id="O2" value="6921.85" spread="4366.14"/>
                    <measurement group_id="O3" value="7096.46" spread="3777.79"/>
                    <measurement group_id="O4" value="7682.43" spread="2951.47"/>
                    <measurement group_id="O5" value="4668.17" spread="1675.47"/>
                    <measurement group_id="O6" value="4713.28" spread="2161.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool Flu [D21] (N=25,25,27,24,24,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5234.16" spread="2513.78"/>
                    <measurement group_id="O2" value="5124.60" spread="2268.53"/>
                    <measurement group_id="O3" value="6579.26" spread="3489.20"/>
                    <measurement group_id="O4" value="6949.96" spread="3006.25"/>
                    <measurement group_id="O5" value="4329.96" spread="1672.20"/>
                    <measurement group_id="O6" value="5691.08" spread="2047.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool Flu [D28] (N=25,27,27,26,25,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4767.36" spread="2217.82"/>
                    <measurement group_id="O2" value="5256.07" spread="2292.16"/>
                    <measurement group_id="O3" value="6090.00" spread="3336.49"/>
                    <measurement group_id="O4" value="7265.23" spread="3520.63"/>
                    <measurement group_id="O5" value="4047.92" spread="1219.00"/>
                    <measurement group_id="O6" value="6804.42" spread="2824.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool Flu [D42] (N=26,27,27,26,24,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4734.42" spread="1823.28"/>
                    <measurement group_id="O2" value="5881.78" spread="2641.14"/>
                    <measurement group_id="O3" value="5721.70" spread="3058.63"/>
                    <measurement group_id="O4" value="6239.38" spread="2542.17"/>
                    <measurement group_id="O5" value="4167.63" spread="1351.74"/>
                    <measurement group_id="O6" value="6215.93" spread="2389.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool Flu [D63] (N=25,26,25,25,24,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4405.96" spread="1586.42"/>
                    <measurement group_id="O2" value="6639.92" spread="3131.66"/>
                    <measurement group_id="O3" value="4893.88" spread="2322.10"/>
                    <measurement group_id="O4" value="5323.84" spread="2132.52"/>
                    <measurement group_id="O5" value="4900.17" spread="2016.61"/>
                    <measurement group_id="O6" value="6455.25" spread="2694.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool Flu [D182] (N=26,24,26,26,25,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3304.50" spread="1393.44"/>
                    <measurement group_id="O2" value="4325.63" spread="1541.34"/>
                    <measurement group_id="O3" value="4006.46" spread="1836.30"/>
                    <measurement group_id="O4" value="3937.67" spread="1413.94"/>
                    <measurement group_id="O5" value="3918.28" spread="1284.32"/>
                    <measurement group_id="O6" value="4277.76" spread="1655.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).</title>
        <description>Influenza-specific CD8 T-Cells were stimulated in vitro with A/California virus and seasonal Influenza viruses, related antigens or derived peptides.
Stimulating antigens were A/Brisbane, A/California, pool peptides H1N1 and pool FLU.</description>
        <time_frame>On Days 0, 7, 21, 28, 42, 63 and 182</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at day 182.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Influenza-specific Cluster of Differentiation 8 (CD8) T-cells Per Million Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L), Interleukin-2 (IL-2), Interferon-γ (IFN-γ) and Tumor Necrosis Factor-α (TNF-α).</title>
          <description>Influenza-specific CD8 T-Cells were stimulated in vitro with A/California virus and seasonal Influenza viruses, related antigens or derived peptides.
Stimulating antigens were A/Brisbane, A/California, pool peptides H1N1 and pool FLU.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at day 182.</population>
          <units>Number of T cells/million</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane [D0] (N=25,25,24,25,25,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="515.36" spread="1191.10"/>
                    <measurement group_id="O2" value="382.84" spread="595.58"/>
                    <measurement group_id="O3" value="489.08" spread="520.30"/>
                    <measurement group_id="O4" value="183.96" spread="226.54"/>
                    <measurement group_id="O5" value="1222.40" spread="4485.04"/>
                    <measurement group_id="O6" value="119.46" spread="113.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [D7] (N=24,27,24,23,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="772.96" spread="716.40"/>
                    <measurement group_id="O2" value="884.81" spread="1225.90"/>
                    <measurement group_id="O3" value="1115.96" spread="1545.07"/>
                    <measurement group_id="O4" value="725.39" spread="585.98"/>
                    <measurement group_id="O5" value="1611.96" spread="4894.45"/>
                    <measurement group_id="O6" value="529.73" spread="416.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [D21] (N=26,25,27,24,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="601.31" spread="1154.73"/>
                    <measurement group_id="O2" value="517.44" spread="799.20"/>
                    <measurement group_id="O3" value="655.22" spread="1327.00"/>
                    <measurement group_id="O4" value="319.17" spread="315.86"/>
                    <measurement group_id="O5" value="1184.17" spread="4146.13"/>
                    <measurement group_id="O6" value="501.08" spread="1319.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [D28] (N=27,27,27,26,25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="629.22" spread="964.11"/>
                    <measurement group_id="O2" value="642.22" spread="850.79"/>
                    <measurement group_id="O3" value="498.33" spread="730.34"/>
                    <measurement group_id="O4" value="508.88" spread="540.73"/>
                    <measurement group_id="O5" value="1466.76" spread="5768.96"/>
                    <measurement group_id="O6" value="1735.48" spread="5219.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [D42] (N=27,26,27,27,24,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="666.67" spread="1180.05"/>
                    <measurement group_id="O2" value="551.88" spread="911.02"/>
                    <measurement group_id="O3" value="525.07" spread="938.18"/>
                    <measurement group_id="O4" value="209.07" spread="171.21"/>
                    <measurement group_id="O5" value="1737.50" spread="6861.67"/>
                    <measurement group_id="O6" value="501.54" spread="1329.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [D63] (N=26,26,25,25,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="620.00" spread="1393.77"/>
                    <measurement group_id="O2" value="420.50" spread="486.62"/>
                    <measurement group_id="O3" value="428.92" spread="687.17"/>
                    <measurement group_id="O4" value="230.84" spread="226.10"/>
                    <measurement group_id="O5" value="1493.46" spread="5828.76"/>
                    <measurement group_id="O6" value="529.81" spread="1383.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane [D182] (N=26,24,26,26,25,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="550.27" spread="1948.06"/>
                    <measurement group_id="O2" value="436.79" spread="653.50"/>
                    <measurement group_id="O3" value="377.65" spread="426.59"/>
                    <measurement group_id="O4" value="86.81" spread="99.38"/>
                    <measurement group_id="O5" value="1474.56" spread="6012.19"/>
                    <measurement group_id="O6" value="370.64" spread="955.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California [D0] (N=25,25,24,25,25,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357.40" spread="800.46"/>
                    <measurement group_id="O2" value="189.28" spread="197.92"/>
                    <measurement group_id="O3" value="271.58" spread="192.68"/>
                    <measurement group_id="O4" value="365.72" spread="985.87"/>
                    <measurement group_id="O5" value="482.64" spread="1286.27"/>
                    <measurement group_id="O6" value="93.50" spread="114.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California [D7] (N=24,27,24,23,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="610.29" spread="744.70"/>
                    <measurement group_id="O2" value="466.93" spread="573.69"/>
                    <measurement group_id="O3" value="716.88" spread="1251.20"/>
                    <measurement group_id="O4" value="553.78" spread="639.15"/>
                    <measurement group_id="O5" value="834.50" spread="2063.34"/>
                    <measurement group_id="O6" value="348.69" spread="326.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California [D21] (N=26,25,27,24,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332.00" spread="539.48"/>
                    <measurement group_id="O2" value="275.04" spread="334.83"/>
                    <measurement group_id="O3" value="324.37" spread="668.77"/>
                    <measurement group_id="O4" value="183.00" spread="146.43"/>
                    <measurement group_id="O5" value="428.92" spread="1071.57"/>
                    <measurement group_id="O6" value="351.69" spread="713.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California [D28] (N=27,27,27,26,25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="470.33" spread="655.02"/>
                    <measurement group_id="O2" value="452.93" spread="547.61"/>
                    <measurement group_id="O3" value="332.63" spread="553.07"/>
                    <measurement group_id="O4" value="344.54" spread="288.96"/>
                    <measurement group_id="O5" value="973.96" spread="3644.93"/>
                    <measurement group_id="O6" value="497.67" spread="612.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California [D42] (N=27,27,27,27,24,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314.89" spread="289.95"/>
                    <measurement group_id="O2" value="304.00" spread="255.38"/>
                    <measurement group_id="O3" value="247.89" spread="459.58"/>
                    <measurement group_id="O4" value="157.67" spread="192.15"/>
                    <measurement group_id="O5" value="702.50" spread="2209.62"/>
                    <measurement group_id="O6" value="291.96" spread="654.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California [D63] (N=26,2625,25,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.62" spread="197.89"/>
                    <measurement group_id="O2" value="260.54" spread="359.88"/>
                    <measurement group_id="O3" value="242.36" spread="357.21"/>
                    <measurement group_id="O4" value="114.24" spread="165.15"/>
                    <measurement group_id="O5" value="853.83" spread="3236.11"/>
                    <measurement group_id="O6" value="194.73" spread="453.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/California [D182] (N=26,24,26,26,25,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214.85" spread="326.43"/>
                    <measurement group_id="O2" value="220.71" spread="330.88"/>
                    <measurement group_id="O3" value="225.50" spread="366.51"/>
                    <measurement group_id="O4" value="139.50" spread="273.43"/>
                    <measurement group_id="O5" value="598.92" spread="2344.64"/>
                    <measurement group_id="O6" value="138.52" spread="245.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool peptides H1 [D0] (N=25,24,24,25,23,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.48" spread="140.31"/>
                    <measurement group_id="O2" value="180.38" spread="359.58"/>
                    <measurement group_id="O3" value="101.04" spread="158.31"/>
                    <measurement group_id="O4" value="150.08" spread="215.56"/>
                    <measurement group_id="O5" value="111.26" spread="162.75"/>
                    <measurement group_id="O6" value="70.92" spread="113.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool peptides H1 [D7] (N=24,27,24,23,24,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205.33" spread="288.67"/>
                    <measurement group_id="O2" value="185.15" spread="243.88"/>
                    <measurement group_id="O3" value="202.13" spread="293.11"/>
                    <measurement group_id="O4" value="254.65" spread="417.53"/>
                    <measurement group_id="O5" value="243.46" spread="382.39"/>
                    <measurement group_id="O6" value="173.48" spread="202.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool peptides H1 [D21] (N=26,24,27,24,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.81" spread="160.76"/>
                    <measurement group_id="O2" value="194.92" spread="384.18"/>
                    <measurement group_id="O3" value="101.30" spread="148.62"/>
                    <measurement group_id="O4" value="140.75" spread="155.63"/>
                    <measurement group_id="O5" value="211.96" spread="482.54"/>
                    <measurement group_id="O6" value="173.77" spread="432.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool peptides H1 [D28] (N=26,27,27,26,25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.08" spread="132.13"/>
                    <measurement group_id="O2" value="170.04" spread="385.99"/>
                    <measurement group_id="O3" value="124.56" spread="181.86"/>
                    <measurement group_id="O4" value="277.77" spread="329.71"/>
                    <measurement group_id="O5" value="160.80" spread="216.87"/>
                    <measurement group_id="O6" value="187.37" spread="361.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool peptides H1 [D42] (N=27,27,27,27,24,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.67" spread="189.28"/>
                    <measurement group_id="O2" value="157.41" spread="350.83"/>
                    <measurement group_id="O3" value="87.41" spread="115.12"/>
                    <measurement group_id="O4" value="103.89" spread="139.95"/>
                    <measurement group_id="O5" value="266.75" spread="481.50"/>
                    <measurement group_id="O6" value="145.96" spread="261.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool peptides H1 [D63] (N=26,26,25,25,24,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.96" spread="97.66"/>
                    <measurement group_id="O2" value="173.88" spread="244.91"/>
                    <measurement group_id="O3" value="113.20" spread="193.78"/>
                    <measurement group_id="O4" value="88.28" spread="162.10"/>
                    <measurement group_id="O5" value="210.33" spread="403.19"/>
                    <measurement group_id="O6" value="88.19" spread="206.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool peptides H1 [D182] (N=26,24,26,26,25,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287.31" spread="511.19"/>
                    <measurement group_id="O2" value="265.63" spread="343.36"/>
                    <measurement group_id="O3" value="306.04" spread="630.16"/>
                    <measurement group_id="O4" value="241.42" spread="353.02"/>
                    <measurement group_id="O5" value="255.44" spread="425.71"/>
                    <measurement group_id="O6" value="198.44" spread="561.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool Flu [D0] (N=24,25,24,25,25,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351.38" spread="467.93"/>
                    <measurement group_id="O2" value="224.60" spread="251.59"/>
                    <measurement group_id="O3" value="478.42" spread="463.43"/>
                    <measurement group_id="O4" value="344.60" spread="641.98"/>
                    <measurement group_id="O5" value="761.68" spread="2411.00"/>
                    <measurement group_id="O6" value="157.63" spread="166.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool Flu [D7] (N=24,27,24,23,24,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="986.92" spread="863.16"/>
                    <measurement group_id="O2" value="843.44" spread="826.65"/>
                    <measurement group_id="O3" value="1042.17" spread="1237.44"/>
                    <measurement group_id="O4" value="788.78" spread="947.53"/>
                    <measurement group_id="O5" value="1094.96" spread="3111.41"/>
                    <measurement group_id="O6" value="522.84" spread="514.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool Flu [D21] (N=25,25,27,24,24,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="586.32" spread="876.08"/>
                    <measurement group_id="O2" value="268.24" spread="324.48"/>
                    <measurement group_id="O3" value="609.07" spread="997.10"/>
                    <measurement group_id="O4" value="266.63" spread="252.28"/>
                    <measurement group_id="O5" value="693.88" spread="2082.82"/>
                    <measurement group_id="O6" value="406.28" spread="620.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool Flu [D28] (N=25,27,27,26,25,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484.48" spread="587.46"/>
                    <measurement group_id="O2" value="508.11" spread="559.97"/>
                    <measurement group_id="O3" value="505.33" spread="595.15"/>
                    <measurement group_id="O4" value="458.12" spread="496.69"/>
                    <measurement group_id="O5" value="963.20" spread="3548.16"/>
                    <measurement group_id="O6" value="423.62" spread="430.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool Flu [D42] (N=26,27,27,26,24,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="506.35" spread="560.83"/>
                    <measurement group_id="O2" value="356.41" spread="392.23"/>
                    <measurement group_id="O3" value="471.30" spread="610.38"/>
                    <measurement group_id="O4" value="344.77" spread="709.66"/>
                    <measurement group_id="O5" value="996.67" spread="3648.68"/>
                    <measurement group_id="O6" value="391.11" spread="755.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool Flu [D63] (N=25,26,25,25,24,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="461.20" spread="698.48"/>
                    <measurement group_id="O2" value="325.12" spread="270.84"/>
                    <measurement group_id="O3" value="402.24" spread="418.89"/>
                    <measurement group_id="O4" value="296.08" spread="624.75"/>
                    <measurement group_id="O5" value="1123.13" spread="4008.27"/>
                    <measurement group_id="O6" value="432.08" spread="1145.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pool Flu [D182] (N=26,24,26,26,25,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404.77" spread="981.01"/>
                    <measurement group_id="O2" value="315.75" spread="441.50"/>
                    <measurement group_id="O3" value="334.23" spread="447.12"/>
                    <measurement group_id="O4" value="291.73" spread="790.15"/>
                    <measurement group_id="O5" value="926.40" spread="3463.27"/>
                    <measurement group_id="O6" value="234.92" spread="398.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed</title>
        <description>Laboratory parameters assessed were alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (AP), bilirubin (BIL) (total (T)), basophils (BAS). For each parameter and for each range it was assessed whether the values of the subjects were in unkown, above, below or within the range.</description>
        <time_frame>On Days 0, 7, 21, 28, 42, 63 and 182</time_frame>
        <population>The Total Vaccinated Cohort included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed</title>
          <description>Laboratory parameters assessed were alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (AP), bilirubin (BIL) (total (T)), basophils (BAS). For each parameter and for each range it was assessed whether the values of the subjects were in unkown, above, below or within the range.</description>
          <population>The Total Vaccinated Cohort included all vaccinated subjects.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALAT [D0] Below (N=102,101,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D0] Within (N=102,101,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D0] Above (N=102,101,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="96"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="96"/>
                    <measurement group_id="O6" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="94"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="93"/>
                    <measurement group_id="O6" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="90"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D0] Below (N=102,104, 102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D0] Within (N=102,104, 102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="99"/>
                    <measurement group_id="O6" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D0] Above (N=102,104, 102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="99"/>
                    <measurement group_id="O6" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="98"/>
                    <measurement group_id="O6" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D42] Below (N=101,97, 95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D42] Within (N=101,97, 95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="92"/>
                    <measurement group_id="O5" value="93"/>
                    <measurement group_id="O6" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D42] Above (N=101,97, 95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="92"/>
                    <measurement group_id="O5" value="95"/>
                    <measurement group_id="O6" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="90"/>
                    <measurement group_id="O5" value="89"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D0] Below (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D0] Within (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="99"/>
                    <measurement group_id="O6" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D0] Above (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="99"/>
                    <measurement group_id="O5" value="99"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="98"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="98"/>
                    <measurement group_id="O6" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="94"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="94"/>
                    <measurement group_id="O5" value="95"/>
                    <measurement group_id="O6" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="88"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D0] Below (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D0] Within (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="102"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="101"/>
                    <measurement group_id="O6" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D0] Above (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="96"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="93"/>
                    <measurement group_id="O6" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D0] Below (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D0] Within (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="102"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="99"/>
                    <measurement group_id="O6" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D0] Above (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="99"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="91"/>
                    <measurement group_id="O5" value="93"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="94"/>
                    <measurement group_id="O5" value="93"/>
                    <measurement group_id="O6" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="90"/>
                    <measurement group_id="O6" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D0] Unknown (N=102,101,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D7] Unknown (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D0] Unknown (N=102,104, 102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D7] Unknown (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D42] Unknown (N=101,97, 95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D0] Unknown (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D7] Unknown (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASAT [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D0] Unknown (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D7] Unknown (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAS [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D0] Unknown (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D7] Unknown (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL T [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed</title>
        <description>Laboratory parameters assessed were creatinine (CREA), bilirubin (BIL) (direct (D)), eosinophils (EOS), hemoglobin (Hgb), hematocrit (Hct). For each parameter and for each range it was assessed whether the values of the subjects were unknown, in above, below or within the range.</description>
        <time_frame>On Days 0, 7, 21, 28, 42, 63 and 182</time_frame>
        <population>The Total Vaccinated cohort included all vaccinated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed</title>
          <description>Laboratory parameters assessed were creatinine (CREA), bilirubin (BIL) (direct (D)), eosinophils (EOS), hemoglobin (Hgb), hematocrit (Hct). For each parameter and for each range it was assessed whether the values of the subjects were unknown, in above, below or within the range.</description>
          <population>The Total Vaccinated cohort included all vaccinated subjects</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BIL D [D0] Below (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D0] Within (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="101"/>
                    <measurement group_id="O4" value="99"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D0] Above (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D0] Unknown (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="99"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D7] Unknown(N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="99"/>
                    <measurement group_id="O6" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="98"/>
                    <measurement group_id="O6" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="94"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="96"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="91"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIL D [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D0] Below (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D0] Within (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="88"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D0] Above (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D0] Unknown (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="91"/>
                    <measurement group_id="O4" value="81"/>
                    <measurement group_id="O5" value="93"/>
                    <measurement group_id="O6" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D7] Unknown (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="81"/>
                    <measurement group_id="O5" value="89"/>
                    <measurement group_id="O6" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="81"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="85"/>
                    <measurement group_id="O6" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="89"/>
                    <measurement group_id="O6" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="80"/>
                    <measurement group_id="O4" value="81"/>
                    <measurement group_id="O5" value="86"/>
                    <measurement group_id="O6" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREA [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D0] Below (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D0] Within (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="92"/>
                    <measurement group_id="O5" value="90"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D0] Above (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D0] Unknown (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="91"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D7] Unknown (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="87"/>
                    <measurement group_id="O5" value="85"/>
                    <measurement group_id="O6" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="90"/>
                    <measurement group_id="O6" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="85"/>
                    <measurement group_id="O6" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="90"/>
                    <measurement group_id="O5" value="88"/>
                    <measurement group_id="O6" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="83"/>
                    <measurement group_id="O5" value="84"/>
                    <measurement group_id="O6" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EOS [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D0] Below (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D0] Within (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="92"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D0] Above (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D0] Unknown (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="92"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D7] Unknown (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="88"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="88"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="88"/>
                    <measurement group_id="O5" value="86"/>
                    <measurement group_id="O6" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="87"/>
                    <measurement group_id="O6" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="82"/>
                    <measurement group_id="O4" value="85"/>
                    <measurement group_id="O5" value="86"/>
                    <measurement group_id="O6" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hct [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D0] Below (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D0] Within (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D0] Above (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D0] Unknown (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="96"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D7] Unknown (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="90"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="96"/>
                    <measurement group_id="O6" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="92"/>
                    <measurement group_id="O5" value="90"/>
                    <measurement group_id="O6" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="91"/>
                    <measurement group_id="O5" value="88"/>
                    <measurement group_id="O6" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="87"/>
                    <measurement group_id="O6" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hgb [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local Symptoms.</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling</description>
        <time_frame>During a 7-day follow-up period (Days 0-6) post-vaccination period</time_frame>
        <population>The Total Vaccinated cohort included all vaccinated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local Symptoms.</title>
          <description>Solicited local symptoms assessed were pain, redness and swelling</description>
          <population>The Total Vaccinated cohort included all vaccinated subjects</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="101"/>
                <count group_id="O6" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="94"/>
                    <measurement group_id="O5" value="69"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited General Symptoms.</title>
        <description>Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature. Temperature is defined as an axillary temperature equal to or above 38.0 degrees Celsius (°C).</description>
        <time_frame>During a 7-day follow-up period (Days 0-6) post-vaccination period</time_frame>
        <population>The Total Vaccinated cohort included all vaccinated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited General Symptoms.</title>
          <description>Solicited general symptoms assessed were fatigue, headache, joint pain at other location, muscle aches, shivering, sweating and temperature. Temperature is defined as an axillary temperature equal to or above 38.0 degrees Celsius (°C).</description>
          <population>The Total Vaccinated cohort included all vaccinated subjects</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="100"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="101"/>
                <count group_id="O6" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="58"/>
                    <measurement group_id="O5" value="57"/>
                    <measurement group_id="O6" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="49"/>
                    <measurement group_id="O6" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint pain at other location</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="53"/>
                    <measurement group_id="O5" value="43"/>
                    <measurement group_id="O6" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature (axillary) &gt;=38°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed</title>
        <description>Laboratory parameters assessed were serum urea nitrogen (SUN), white blood cells (WBC), red blood cells (RBC). For each parameter and for each range it was assessed whether the values of the subjects were unknown, above, below or within the range.</description>
        <time_frame>On Days 0, 7, 21, 28, 42, 63 and 182</time_frame>
        <population>The Total Vaccinated cohort included all vaccinated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed</title>
          <description>Laboratory parameters assessed were serum urea nitrogen (SUN), white blood cells (WBC), red blood cells (RBC). For each parameter and for each range it was assessed whether the values of the subjects were unknown, above, below or within the range.</description>
          <population>The Total Vaccinated cohort included all vaccinated subjects</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RBC [D0] Below (N=102,104,102,100101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D0] Within (N=102,104,102,100101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="99"/>
                    <measurement group_id="O6" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D0] Above (N=102,104,102,100101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D0] Unknown (N=102,104,102,100101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="95"/>
                    <measurement group_id="O6" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D7] Unknown (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="90"/>
                    <measurement group_id="O5" value="94"/>
                    <measurement group_id="O6" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="95"/>
                    <measurement group_id="O6" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="89"/>
                    <measurement group_id="O6" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="88"/>
                    <measurement group_id="O6" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D0] Below (N=102,104,102,100101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D0] Within (N=102,104,102,100101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="98"/>
                    <measurement group_id="O6" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D0] Above (N=102,104,102,100101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D0] Unknown (N=102,104,102,100101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="99"/>
                    <measurement group_id="O6" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D7] Unknown (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="98"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="98"/>
                    <measurement group_id="O6" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="91"/>
                    <measurement group_id="O4" value="94"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="96"/>
                    <measurement group_id="O6" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="90"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUN [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D0] Below (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D0] Within (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="95"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D0] Above (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D0] Unknown (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="98"/>
                    <measurement group_id="O4" value="92"/>
                    <measurement group_id="O5" value="94"/>
                    <measurement group_id="O6" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D7] Unknown (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="92"/>
                    <measurement group_id="O5" value="93"/>
                    <measurement group_id="O6" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="90"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="82"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="88"/>
                    <measurement group_id="O6" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs).</title>
        <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>Within the 84-day (Days 0-83) post-vaccination period.</time_frame>
        <population>The Total Vaccinated Cohort included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs).</title>
          <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>The Total Vaccinated Cohort included all vaccinated subjects.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="57"/>
                    <measurement group_id="O5" value="62"/>
                    <measurement group_id="O6" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Medically Attended Visits (MAEs).</title>
        <description>The day 368 was the last contact day for the last subject reporting the event. For each solicited and unsolicited symptom the subject experienced, the subject was asked if they received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel for any reason.</description>
        <time_frame>During the entire study period (Days 0-368).</time_frame>
        <population>The Total Vaccinated Cohort included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Medically Attended Visits (MAEs).</title>
          <description>The day 368 was the last contact day for the last subject reporting the event. For each solicited and unsolicited symptom the subject experienced, the subject was asked if they received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel for any reason.</description>
          <population>The Total Vaccinated Cohort included all vaccinated subjects.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="42"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Potential Immune Diseases (pIMDs).</title>
        <description>The day 406 was the last contact day with the subjects reporting the event. Potential immune-mediated diseases (pIMDs) are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.</description>
        <time_frame>During the entire study period (Days 0-406).</time_frame>
        <population>The Total Vaccinated Cohort included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Potential Immune Diseases (pIMDs).</title>
          <description>The day 406 was the last contact day with the subjects reporting the event. Potential immune-mediated diseases (pIMDs) are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.</description>
          <population>The Total Vaccinated Cohort included all vaccinated subjects.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs).</title>
        <description>The day 329 was the last contact day with the subjects reporting serious adverse events.
SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.</description>
        <time_frame>During the entire study period (Days 0-329).</time_frame>
        <population>The Total Vaccinated Cohort included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs).</title>
          <description>The day 329 was the last contact day with the subjects reporting serious adverse events.
SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.</description>
          <population>The Total Vaccinated Cohort included all vaccinated subjects.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed</title>
        <description>Laboratory parameters assessed were neutrophils (NEU), lymphocytes (LYM), monocytes (MON) and platelets (PLA). For each parameter and for each range it was assessed whether the values of the subjects were unknown, in above, below or within the range.</description>
        <time_frame>On Days 0, 7, 21, 28, 42, 63 and 182</time_frame>
        <population>The Total Vaccinated cohort included all vaccinated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemical and Haematological Parameters Assessed</title>
          <description>Laboratory parameters assessed were neutrophils (NEU), lymphocytes (LYM), monocytes (MON) and platelets (PLA). For each parameter and for each range it was assessed whether the values of the subjects were unknown, in above, below or within the range.</description>
          <population>The Total Vaccinated cohort included all vaccinated subjects</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
                <count group_id="O6" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LYM [D0] Below (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D0] Within (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="102"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="101"/>
                    <measurement group_id="O6" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D0] Above (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D0] Unknown (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D7] Unknown (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="94"/>
                    <measurement group_id="O5" value="93"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="96"/>
                    <measurement group_id="O6" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LYM [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D0] Below (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D0] Within (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="79"/>
                    <measurement group_id="O5" value="88"/>
                    <measurement group_id="O6" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D0] Above (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D0] Unknown (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="86"/>
                    <measurement group_id="O5" value="87"/>
                    <measurement group_id="O6" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D7] Unknown (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="79"/>
                    <measurement group_id="O6" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="70"/>
                    <measurement group_id="O5" value="80"/>
                    <measurement group_id="O6" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="70"/>
                    <measurement group_id="O5" value="76"/>
                    <measurement group_id="O6" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="82"/>
                    <measurement group_id="O6" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="68"/>
                    <measurement group_id="O5" value="73"/>
                    <measurement group_id="O6" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MON [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D0] Below (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D0] Within (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="92"/>
                    <measurement group_id="O5" value="98"/>
                    <measurement group_id="O6" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D0] Above (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D0] Unknown (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D7] Below (N=101,100,98,97,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D7] Within (N=101,100,98,97,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="90"/>
                    <measurement group_id="O5" value="93"/>
                    <measurement group_id="O6" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D7] Above (N=101,100,98,97,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D7] Unknown (N=101,100,98,97,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="91"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="93"/>
                    <measurement group_id="O6" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="92"/>
                    <measurement group_id="O5" value="93"/>
                    <measurement group_id="O6" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="92"/>
                    <measurement group_id="O5" value="92"/>
                    <measurement group_id="O6" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="86"/>
                    <measurement group_id="O5" value="89"/>
                    <measurement group_id="O6" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEU [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D0] Below (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D0] Within (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="102"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="98"/>
                    <measurement group_id="O6" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D0] Above (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D0] Unknown (N=102,104,102,100,101,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D7] Below (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D7] Within (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="97"/>
                    <measurement group_id="O5" value="99"/>
                    <measurement group_id="O6" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D7] Above (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D7] Unknown (N=102,101,100,99,100,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D21] Below (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D21] Within (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D21] Above (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D21] Unknown (N=101,100,97,97,99,99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D28] Below (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D28] Within (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="96"/>
                    <measurement group_id="O5" value="95"/>
                    <measurement group_id="O6" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D28] Above (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D28] Unknown (N=101,98,96,98,98,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D42] Below (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D42] Within (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="93"/>
                    <measurement group_id="O6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D42] Above (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D42] Unknown (N=101,97,95,95,96,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D63] Below (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D63] Within (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="96"/>
                    <measurement group_id="O6" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D63] Above (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D63] Unknown (N=100,95,95,95,97,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D182] Below (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D182] Within (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="87"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D182] Above (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PLA [D182] Unknown (N=99,91,88,91,93,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microneutralization Antibody Titers Against A/California/7/2009 (H1N1) Strain.</title>
        <description>Titers were expressed as geometric mean titers (GMTs) and measured by microneutralization.
Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1).
Microneutralization testing was cancelled.</description>
        <time_frame>On Days 0, 21, 42, 63 and 182</time_frame>
        <population>Microneutralization testing was cancelled.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Microneutralization Antibody Titers Against A/California/7/2009 (H1N1) Strain.</title>
          <description>Titers were expressed as geometric mean titers (GMTs) and measured by microneutralization.
Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1).
Microneutralization testing was cancelled.</description>
          <population>Microneutralization testing was cancelled.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Microneutralization Titer Greater Than or Equal to 1:28 for Antibodies Against A/California/7/2009 (H1N1) Strain.</title>
        <description>Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1).
The antibody cut-off value assessed was a titer of 1:10 and this value was considered as seropositivity.
Seronegative subject is a subject whose antibody titer is below the cut-off value, a seropositive subject is a subject whose antibody titer is greater than or equal to the cut-off value. Microneutralization titers &lt; 1:28 were considered below the cut-off.
Microneutralization testing was cancelled.</description>
        <time_frame>On Days 0, 21, 42, 63 and 182</time_frame>
        <population>Microneutralization testing was cancelled.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Microneutralization Titer Greater Than or Equal to 1:28 for Antibodies Against A/California/7/2009 (H1N1) Strain.</title>
          <description>Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1).
The antibody cut-off value assessed was a titer of 1:10 and this value was considered as seropositivity.
Seronegative subject is a subject whose antibody titer is below the cut-off value, a seropositive subject is a subject whose antibody titer is greater than or equal to the cut-off value. Microneutralization titers &lt; 1:28 were considered below the cut-off.
Microneutralization testing was cancelled.</description>
          <population>Microneutralization testing was cancelled.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Response Rates (VRR) for Microneutralization Antibody Titers Against A/California/7/2009 (H1N1) Strain.</title>
        <description>Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1).
Vaccine Response Rate for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0.
Microneutralization testing was cancelled.</description>
        <time_frame>On Days 0, 21, 42, 63 and 182</time_frame>
        <population>Microneutralization testing was cancelled.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Response Rates (VRR) for Microneutralization Antibody Titers Against A/California/7/2009 (H1N1) Strain.</title>
          <description>Arepanrix vaccine strain and the unadjuvanted formulation of Arepanrix vaccine strain was A/California/7/2009 (H1N1).
Vaccine Response Rate for microneutralization titers was defined as the incidence rate of vaccinees with at least a 4-fold increase in post vaccination reciprocal titer relative to Day 0.
Microneutralization testing was cancelled.</description>
          <population>Microneutralization testing was cancelled.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.</title>
        <description>The A/California vaccine virus-homologous antibody response was measured in subjects having received Flulaval vaccine co-administered with the first dose of Arepanrix vaccine, and in subjects having received two doses of Arepanrix vaccine alone.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>21 days after the second dose of Arepanrix vaccine (at Day 42).</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.</title>
          <description>The A/California vaccine virus-homologous antibody response was measured in subjects having received Flulaval vaccine co-administered with the first dose of Arepanrix vaccine, and in subjects having received two doses of Arepanrix vaccine alone.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="589.8" lower_limit="517.8" upper_limit="671.8"/>
                    <measurement group_id="O6" value="933.1" lower_limit="815.6" upper_limit="1067.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.</title>
        <description>The A/California vaccine virus-homologous antibody response was measured in subjects having received Flulaval vaccine co-administered with the first dose of the unadjuvanted formulation of Arepanrix vaccine, and in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine alone.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>21 days after the second dose of the unadjuvanted formulation of Arepanrix vaccine (at Day 42)</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.</title>
          <description>The A/California vaccine virus-homologous antibody response was measured in subjects having received Flulaval vaccine co-administered with the first dose of the unadjuvanted formulation of Arepanrix vaccine, and in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine alone.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="271.2" lower_limit="224.6" upper_limit="327.4"/>
                    <measurement group_id="O5" value="387.1" lower_limit="314.4" upper_limit="476.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.</title>
        <description>The A/California vaccine virus-homologous antibody response was measured in subjects having received two doses of Arepanrix vaccine, with prior treatment with Flulaval vaccine 21 days before the first dose and in subjects having received two doses of Arepanrix vaccine alone.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>21 days after the second dose of Arepanrix vaccine (Day 63 for Flulaval/placebo/Arepanrix Group and Day 42 for Arepanrix/placebo/Flulaval Group)</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.</title>
          <description>The A/California vaccine virus-homologous antibody response was measured in subjects having received two doses of Arepanrix vaccine, with prior treatment with Flulaval vaccine 21 days before the first dose and in subjects having received two doses of Arepanrix vaccine alone.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="645.2" lower_limit="557.6" upper_limit="746.6"/>
                    <measurement group_id="O6" value="933.1" lower_limit="815.6" upper_limit="1067.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.</title>
        <description>The A/California vaccine virus-homologous antibody response was measured in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine, with prior treatment with Flulaval vaccine 21 days before the first dose and in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine alone.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>21 days after the second dose of the unadjuvanted formulation of Arepanrix vaccine (Day 63 for Flulaval/placebo/unadjuvanted Arepanrix Group and Day 42 for Unadjuvanted Arepanrix/placebo/Flulaval Group)</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.</title>
          <description>The A/California vaccine virus-homologous antibody response was measured in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine, with prior treatment with Flulaval vaccine 21 days before the first dose and in subjects having received two doses of the unadjuvanted formulation of Arepanrix vaccine alone.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.2" lower_limit="210.1" upper_limit="307.7"/>
                    <measurement group_id="O5" value="387.1" lower_limit="314.4" upper_limit="476.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.</title>
        <description>The A/California vaccine virus-homologous antibody response was measured in subjects pre-treated with Flulaval who subsequently received two doses of the unadjuvanted formulation of Arepanrix vaccine compared to subjects pre-treated with Flulaval vaccine who subsequently received two doses of Arepanrix vaccine.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>21 days after the second dose of the pandemic vaccine (at Day 63)</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition (HI) Antibody Titers Against A/California/7/2009 H1N1 Vaccine Strain.</title>
          <description>The A/California vaccine virus-homologous antibody response was measured in subjects pre-treated with Flulaval who subsequently received two doses of the unadjuvanted formulation of Arepanrix vaccine compared to subjects pre-treated with Flulaval vaccine who subsequently received two doses of Arepanrix vaccine.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.2" lower_limit="210.1" upper_limit="307.7"/>
                    <measurement group_id="O2" value="645.2" lower_limit="557.6" upper_limit="746.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.</title>
        <description>The antibody response against each of the three Flulaval vaccine components in subjects exposed to co-administration of Flulaval vaccine with the first of two doses of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.
Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>21 days after the Flulaval vaccination (at Day 21).</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.</title>
          <description>The antibody response against each of the three Flulaval vaccine components in subjects exposed to co-administration of Flulaval vaccine with the first of two doses of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.
Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/BRI/59/07 H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.1" lower_limit="115.9" upper_limit="181.6"/>
                    <measurement group_id="O2" value="215.7" lower_limit="168.2" upper_limit="276.5"/>
                    <measurement group_id="O4" value="158.7" lower_limit="127.9" upper_limit="197.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.7" lower_limit="129.6" upper_limit="238.2"/>
                    <measurement group_id="O2" value="183.5" lower_limit="135.2" upper_limit="248.9"/>
                    <measurement group_id="O4" value="191.4" lower_limit="138.4" upper_limit="264.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="662.1" lower_limit="545.4" upper_limit="803.8"/>
                    <measurement group_id="O2" value="658.3" lower_limit="540.2" upper_limit="802.0"/>
                    <measurement group_id="O4" value="576.1" lower_limit="479.8" upper_limit="691.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.</title>
        <description>The antibody response against each of the three Flulaval vaccine components in subjects exposed to co-administration of Flulaval vaccine with the first of two doses of the unadjuvanted formulation of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.
Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>21 days after the Flulaval vaccination (at Day 21).</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.</title>
          <description>The antibody response against each of the three Flulaval vaccine components in subjects exposed to co-administration of Flulaval vaccine with the first of two doses of the unadjuvanted formulation of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.
Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/Brisbane/59/07 H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.1" lower_limit="115.9" upper_limit="181.6"/>
                    <measurement group_id="O2" value="215.7" lower_limit="168.2" upper_limit="276.5"/>
                    <measurement group_id="O3" value="226.3" lower_limit="181.4" upper_limit="282.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.7" lower_limit="129.6" upper_limit="238.2"/>
                    <measurement group_id="O2" value="183.5" lower_limit="135.2" upper_limit="248.9"/>
                    <measurement group_id="O3" value="181.7" lower_limit="128.1" upper_limit="257.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Brisbane/60/08</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="662.1" lower_limit="545.4" upper_limit="803.8"/>
                    <measurement group_id="O2" value="658.3" lower_limit="540.2" upper_limit="802.0"/>
                    <measurement group_id="O3" value="478.8" lower_limit="389.5" upper_limit="588.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.</title>
        <description>The antibody response against each of the three Flulaval vaccine components in subjects exposed to pre-treatment with two doses of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.
Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>21 days after the Flulaval vaccination (Day 63 for Arepanrix/placebo/Flulaval Group and Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups)</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.</title>
          <description>The antibody response against each of the three Flulaval vaccine components in subjects exposed to pre-treatment with two doses of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.
Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/BRI/59/07 H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.1" lower_limit="115.9" upper_limit="181.6"/>
                    <measurement group_id="O2" value="215.7" lower_limit="168.2" upper_limit="276.5"/>
                    <measurement group_id="O6" value="166.9" lower_limit="132.5" upper_limit="210.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.7" lower_limit="129.6" upper_limit="238.2"/>
                    <measurement group_id="O2" value="183.5" lower_limit="135.2" upper_limit="248.9"/>
                    <measurement group_id="O6" value="221.9" lower_limit="167.2" upper_limit="294.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="662.1" lower_limit="545.4" upper_limit="803.8"/>
                    <measurement group_id="O2" value="658.3" lower_limit="540.2" upper_limit="802.0"/>
                    <measurement group_id="O6" value="688.1" lower_limit="593.0" upper_limit="798.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.</title>
        <description>The antibody response against each of the three Flulaval vaccine components in subjects exposed to pre-treatment with two doses of the unadjuvanted formulation of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.
Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>21 days after the Flulaval vaccination (Day 63 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups)</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Flulaval Strains.</title>
          <description>The antibody response against each of the three Flulaval vaccine components in subjects exposed to pre-treatment with two doses of the unadjuvanted formulation of Arepanrix vaccine and in subjects exposed to a single dose of Flulaval vaccine.
Flulaval vaccine strains were Flu A/Brisbane/59/2007 H1N1, Flu A/Uruguay/716/2007 H3N2 and Flu B/Brisbane/60/2008.
Titers were expressed as geometric mean antibody titers (GMTs).</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/Bri/59/07 H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.1" lower_limit="115.9" upper_limit="181.6"/>
                    <measurement group_id="O2" value="215.7" lower_limit="168.2" upper_limit="276.5"/>
                    <measurement group_id="O5" value="137.4" lower_limit="109.0" upper_limit="173.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.7" lower_limit="129.6" upper_limit="238.2"/>
                    <measurement group_id="O2" value="183.5" lower_limit="135.2" upper_limit="248.9"/>
                    <measurement group_id="O5" value="216.1" lower_limit="160.0" upper_limit="292.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="662.1" lower_limit="545.4" upper_limit="803.8"/>
                    <measurement group_id="O2" value="658.3" lower_limit="540.2" upper_limit="802.0"/>
                    <measurement group_id="O5" value="644.9" lower_limit="534.5" upper_limit="778.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.</title>
        <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>On Days 0, 21, 42 and 63</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.</title>
          <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/Cal H1N1 [at Day 0] (N=92;86;92;88;91;91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="11.2" upper_limit="19.0"/>
                    <measurement group_id="O2" value="10.9" lower_limit="8.7" upper_limit="13.6"/>
                    <measurement group_id="O3" value="13.0" lower_limit="10.2" upper_limit="16.5"/>
                    <measurement group_id="O4" value="10.7" lower_limit="8.2" upper_limit="14.0"/>
                    <measurement group_id="O5" value="9.3" lower_limit="7.7" upper_limit="11.4"/>
                    <measurement group_id="O6" value="10.1" lower_limit="8.2" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Cal H1N1 [at Day 21] (N=92;86;92;89;91;91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" lower_limit="24.0" upper_limit="40.3"/>
                    <measurement group_id="O2" value="26.3" lower_limit="19.9" upper_limit="34.8"/>
                    <measurement group_id="O3" value="277.3" lower_limit="222.4" upper_limit="345.7"/>
                    <measurement group_id="O4" value="361.0" lower_limit="301.5" upper_limit="432.2"/>
                    <measurement group_id="O5" value="358.7" lower_limit="285.0" upper_limit="451.4"/>
                    <measurement group_id="O6" value="659.8" lower_limit="546.0" upper_limit="797.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Cal H1N1 [at Day 42] (N=92;86;92;89;91;91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238.6" lower_limit="191.8" upper_limit="296.7"/>
                    <measurement group_id="O2" value="396.2" lower_limit="329.2" upper_limit="476.8"/>
                    <measurement group_id="O3" value="271.2" lower_limit="224.6" upper_limit="327.4"/>
                    <measurement group_id="O4" value="589.8" lower_limit="517.8" upper_limit="671.8"/>
                    <measurement group_id="O5" value="387.1" lower_limit="314.4" upper_limit="476.7"/>
                    <measurement group_id="O6" value="933.1" lower_limit="815.6" upper_limit="1067.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Cal H1N1 [at Day 63] (N=92;86;92;89;91;91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.2" lower_limit="210.1" upper_limit="307.7"/>
                    <measurement group_id="O2" value="645.2" lower_limit="557.6" upper_limit="746.6"/>
                    <measurement group_id="O3" value="245.0" lower_limit="200.7" upper_limit="299.1"/>
                    <measurement group_id="O4" value="426.9" lower_limit="373.0" upper_limit="488.5"/>
                    <measurement group_id="O5" value="345.3" lower_limit="278.6" upper_limit="428.0"/>
                    <measurement group_id="O6" value="704.0" lower_limit="602.1" upper_limit="823.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.</title>
        <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
        <time_frame>At Day 182</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at Day 182.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flu A/California H1N1 Strain.</title>
          <description>Titers were expressed as geometric mean antibody titers (GMTs).</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at Day 182.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="89"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.6" lower_limit="108.6" upper_limit="171.9"/>
                    <measurement group_id="O2" value="206.9" lower_limit="171.3" upper_limit="249.9"/>
                    <measurement group_id="O3" value="151.7" lower_limit="119.1" upper_limit="193.2"/>
                    <measurement group_id="O4" value="171.7" lower_limit="143.2" upper_limit="205.8"/>
                    <measurement group_id="O5" value="218.5" lower_limit="169.8" upper_limit="281.1"/>
                    <measurement group_id="O6" value="323.6" lower_limit="268.8" upper_limit="389.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects for Antibodies Against A/ California Strain.</title>
        <description>Seroconversion rate was defined as the incidence rate of vaccinees who had either a pre-vaccination titer recorded as &lt; 1:10 and a post-vaccination reciprocal titer ≥ 40 or a pre-vaccination reciprocal titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer.
Seroconversion defined as:
For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer</description>
        <time_frame>At Day 63 from Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups; At Day 42 from Day 0 for the 4 other groups</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects for Antibodies Against A/ California Strain.</title>
          <description>Seroconversion rate was defined as the incidence rate of vaccinees who had either a pre-vaccination titer recorded as &lt; 1:10 and a post-vaccination reciprocal titer ≥ 40 or a pre-vaccination reciprocal titer ≥ 10 and at least a 4-fold increase in post vaccination reciprocal titer.
Seroconversion defined as:
For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="85"/>
                    <measurement group_id="O5" value="88"/>
                    <measurement group_id="O6" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects for Antibodies Against A/California Strain.</title>
        <description>Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.</description>
        <time_frame>At Day 63 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups; At Day 42 for the 4 other groups.</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects for Antibodies Against A/California Strain.</title>
          <description>Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Antibodies Against A/California Strain.</title>
        <description>Seroconversion factor was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the prevaccination reciprocal HI titer.</description>
        <time_frame>At Day 63 from Day 21 for Flulaval/placebo/unadjuvanted Arepanrix and Flulaval/placebo/Arepanrix Groups; At Day 42 from Day 0 for the 4 other groups</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Antibodies Against A/California Strain.</title>
          <description>Seroconversion factor was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the prevaccination reciprocal HI titer.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Fold</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="6.4" upper_limit="10.5"/>
                    <measurement group_id="O2" value="24.6" lower_limit="18.1" upper_limit="33.3"/>
                    <measurement group_id="O3" value="20.9" lower_limit="16.3" upper_limit="26.7"/>
                    <measurement group_id="O4" value="54.9" lower_limit="42.1" upper_limit="71.7"/>
                    <measurement group_id="O5" value="41.5" lower_limit="32.4" upper_limit="53.2"/>
                    <measurement group_id="O6" value="92.4" lower_limit="73.3" upper_limit="116.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.</title>
        <description>Seroconversion defined as:
For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.
For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.</description>
        <time_frame>At Day 21 from Day 0 for the pooled group, Flulaval/unadjuvanted Arepanrix/placebo and Flulaval/Arepanrix/placebo Groups; at Day 63 from Day 42 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Arepanrix/placebo/Flulaval Group</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>Flulaval/Placebo/(Unadjuvanted) Arepanrix Pooled Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the (unadjuvanted formulation of ) Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains.</title>
          <description>Seroconversion defined as:
For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.
For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="91"/>
                <count group_id="O7" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/Bri/59/07 H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="70"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="33"/>
                    <measurement group_id="O7" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="73"/>
                    <measurement group_id="O6" value="72"/>
                    <measurement group_id="O7" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="71"/>
                    <measurement group_id="O6" value="57"/>
                    <measurement group_id="O7" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains</title>
        <description>Seroprotection was defined as the proportion of subjects with H1N1 reciprocal Hemagglutination Inhibition (HI) titers ≥ 1:40 against the tested vaccine virus.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.
For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.</description>
        <time_frame>At Day 21 for the pooled group, Flulaval/unadjuvanted Arepanrix/placebo and Flulaval/Arepanrix/placebo Groups; at Day 63 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Arepanrix/placebo/Flulaval Group</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>Flulaval/Placebo/(Unadjuvanted) Arepanrix Pooled Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the (unadjuvanted formulation of ) Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains</title>
          <description>Seroprotection was defined as the proportion of subjects with H1N1 reciprocal Hemagglutination Inhibition (HI) titers ≥ 1:40 against the tested vaccine virus.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.
For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="91"/>
                <count group_id="O7" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/Bri/59/07 H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="82"/>
                    <measurement group_id="O5" value="81"/>
                    <measurement group_id="O6" value="87"/>
                    <measurement group_id="O7" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="79"/>
                    <measurement group_id="O5" value="81"/>
                    <measurement group_id="O6" value="83"/>
                    <measurement group_id="O7" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="91"/>
                    <measurement group_id="O7" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.</title>
        <description>Seroconversion factor was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal Hemagglutination Inhibition (HI) titer to the prevaccination reciprocal HI titer.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.
For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.</description>
        <time_frame>At Day 21 from Day 0 for the pooled group, Flulaval/unadjuvanted Arepanrix/placebo and Flulaval/Arepanrix/placebo Groups; at Day 63 from Day 42 for Unadjuvanted Arepanrix/placebo/Flulaval Group and Arepanrix/placebo/Flulaval Group</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O7">
            <title>Flulaval/Placebo/(Unadjuvanted) Arepanrix Pooled Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the (unadjuvanted formulation of ) Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.</title>
          <description>Seroconversion factor was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal Hemagglutination Inhibition (HI) titer to the prevaccination reciprocal HI titer.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.
For the analysis the Flulaval/placebo/unadjuvanted Arepanrix Group and the Flulaval/placebo/Arepanrix Group were pooled.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Fold</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="91"/>
                <count group_id="O7" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/Bri/59/07 H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="12.0" lower_limit="9.4" upper_limit="15.4"/>
                    <measurement group_id="O4" value="9.6" lower_limit="7.7" upper_limit="12.1"/>
                    <measurement group_id="O5" value="4.2" lower_limit="3.5" upper_limit="5.0"/>
                    <measurement group_id="O6" value="3.1" lower_limit="2.5" upper_limit="3.9"/>
                    <measurement group_id="O7" value="10.3" lower_limit="8.6" upper_limit="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="20.6" lower_limit="14.8" upper_limit="28.6"/>
                    <measurement group_id="O4" value="19.3" lower_limit="14.2" upper_limit="26.4"/>
                    <measurement group_id="O5" value="17.3" lower_limit="12.8" upper_limit="23.2"/>
                    <measurement group_id="O6" value="11.6" lower_limit="8.9" upper_limit="15.2"/>
                    <measurement group_id="O7" value="16.5" lower_limit="13.5" upper_limit="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="10.5" lower_limit="8.3" upper_limit="13.5"/>
                    <measurement group_id="O4" value="14.3" lower_limit="11.0" upper_limit="18.7"/>
                    <measurement group_id="O5" value="8.6" lower_limit="7.0" upper_limit="10.7"/>
                    <measurement group_id="O6" value="4.9" lower_limit="4.1" upper_limit="6.0"/>
                    <measurement group_id="O7" value="13.2" lower_limit="11.1" upper_limit="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains</title>
        <description>Seroconversion defined as:
For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
        <time_frame>on Days 21 and 63 from Day 0 for the first 4 groups; on Days 42 and 63 from Day 0 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains</title>
          <description>Seroconversion defined as:
For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/Bri/59/07 H1N1 [Day 21 or 42 after dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="70"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Bri/59/07 H1N1 [Day 63 after dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="71"/>
                    <measurement group_id="O6" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2 [Day 21 or 42 after dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="76"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2 [Day 63 after dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="69"/>
                    <measurement group_id="O5" value="75"/>
                    <measurement group_id="O6" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08 [Day 21 or 42 after dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="78"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08 [Day 63 after dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="73"/>
                    <measurement group_id="O5" value="78"/>
                    <measurement group_id="O6" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains</title>
        <description>Seroconversion defined as:
For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
        <time_frame>At Day 182 from Day 0</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at Day 182.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects for Antibodies Against Flulaval Vaccine Strains</title>
          <description>Seroconversion defined as:
For initially seronegative subjects, antibody titer ≥ 1:40 after vaccination For initially seropositive subjects, antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at Day 182.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="89"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/Bri/59/07 H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="46"/>
                    <measurement group_id="O6" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="56"/>
                    <measurement group_id="O5" value="60"/>
                    <measurement group_id="O6" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08 Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="67"/>
                    <measurement group_id="O6" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.</title>
        <description>Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
        <time_frame>before vaccination and on days 21 and 63 for the first 4 groups and before vaccination and on days 42 and 63 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.</title>
          <description>Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/Bri/59/07 H1N1 [at Day 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="23"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Bri/59/07 H1N1 [Days 21 or 42 post dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="82"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="79"/>
                    <measurement group_id="O5" value="81"/>
                    <measurement group_id="O6" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2 [at Day 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2 [Days 21 or 42 post dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="79"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="75"/>
                    <measurement group_id="O5" value="81"/>
                    <measurement group_id="O6" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08 [at Day 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="49"/>
                    <measurement group_id="O5" value="66"/>
                    <measurement group_id="O6" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08 [Days 21 or 42 post dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="75"/>
                    <measurement group_id="O6" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08 [at Day 63 post dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="91"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.</title>
        <description>Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
        <time_frame>At Day 182 after the first dose</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at Day 182.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects for Antibodies Against Flulaval Vaccine Strains.</title>
          <description>Seroprotection rate was defined as the proportion of subjects with H1N1 reciprocal HI titers ≥ 40 against the tested vaccine virus.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at Day 182.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="89"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/Bri/59/07 H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="67"/>
                    <measurement group_id="O6" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="68"/>
                    <measurement group_id="O6" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08 Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="79"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="88"/>
                    <measurement group_id="O6" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.</title>
        <description>Seroconversion factor of the within-subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
        <time_frame>On Days 21 and 63 from Day 0 for the first 4 groups and on Days 42 and 63 from Day 0 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.</title>
          <description>Seroconversion factor of the within-subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Fold</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/Bri/59/07 H1N1 [Day 21 or 42 post dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="6.5" upper_limit="10.8"/>
                    <measurement group_id="O2" value="12.9" lower_limit="10.0" upper_limit="16.6"/>
                    <measurement group_id="O3" value="12.0" lower_limit="9.4" upper_limit="15.4"/>
                    <measurement group_id="O4" value="9.6" lower_limit="7.7" upper_limit="12.1"/>
                    <measurement group_id="O5" value="2.3" lower_limit="1.9" upper_limit="2.6"/>
                    <measurement group_id="O6" value="3.2" lower_limit="2.7" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Bri/59/07 H1N1 [at Day 63 post dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="5.4" upper_limit="8.9"/>
                    <measurement group_id="O2" value="11.2" lower_limit="9.1" upper_limit="13.7"/>
                    <measurement group_id="O3" value="8.4" lower_limit="6.6" upper_limit="10.6"/>
                    <measurement group_id="O4" value="7.6" lower_limit="6.0" upper_limit="9.5"/>
                    <measurement group_id="O5" value="9.4" lower_limit="7.6" upper_limit="11.7"/>
                    <measurement group_id="O6" value="10.1" lower_limit="8.1" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2 [Day 21 or 42 post dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="13.0" upper_limit="23.3"/>
                    <measurement group_id="O2" value="15.5" lower_limit="11.8" upper_limit="20.4"/>
                    <measurement group_id="O3" value="20.6" lower_limit="14.8" upper_limit="28.6"/>
                    <measurement group_id="O4" value="19.3" lower_limit="14.2" upper_limit="26.4"/>
                    <measurement group_id="O5" value="1.2" lower_limit="1.1" upper_limit="1.4"/>
                    <measurement group_id="O6" value="1.7" lower_limit="1.5" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2 [at Day 63 post dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="10.0" upper_limit="17.6"/>
                    <measurement group_id="O2" value="11.7" lower_limit="9.1" upper_limit="15.0"/>
                    <measurement group_id="O3" value="15.0" lower_limit="11.2" upper_limit="19.9"/>
                    <measurement group_id="O4" value="14.6" lower_limit="10.9" upper_limit="19.6"/>
                    <measurement group_id="O5" value="20.8" lower_limit="15.5" upper_limit="28.0"/>
                    <measurement group_id="O6" value="19.3" lower_limit="14.6" upper_limit="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B:Bri/60/08 [Day 21 or 42 post dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" lower_limit="9.8" upper_limit="16.2"/>
                    <measurement group_id="O2" value="13.9" lower_limit="11.1" upper_limit="17.5"/>
                    <measurement group_id="O3" value="10.5" lower_limit="8.3" upper_limit="13.5"/>
                    <measurement group_id="O4" value="14.3" lower_limit="11.0" upper_limit="18.7"/>
                    <measurement group_id="O5" value="1.3" lower_limit="1.1" upper_limit="1.5"/>
                    <measurement group_id="O6" value="2.4" lower_limit="2.0" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08 [at Day 63 post dose 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="7.5" upper_limit="12.4"/>
                    <measurement group_id="O2" value="10.0" lower_limit="8.1" upper_limit="12.2"/>
                    <measurement group_id="O3" value="7.9" lower_limit="6.3" upper_limit="9.9"/>
                    <measurement group_id="O4" value="10.8" lower_limit="8.4" upper_limit="13.7"/>
                    <measurement group_id="O5" value="11.4" lower_limit="9.1" upper_limit="14.2"/>
                    <measurement group_id="O6" value="11.9" lower_limit="9.4" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.</title>
        <description>Seroconversion factor of the within-subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
        <time_frame>At Day 182 from Day 0</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at Day 182.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Antibodies Against Flulaval Vaccine Strains.</title>
          <description>Seroconversion factor of the within-subject ratios of the post-vaccination reciprocal HI titer to the Day 0 reciprocal HI titer.
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at Day 182.</population>
          <units>Fold</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="89"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/Bri/59/07 H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.1" upper_limit="5.3"/>
                    <measurement group_id="O2" value="5.2" lower_limit="4.2" upper_limit="6.6"/>
                    <measurement group_id="O3" value="4.7" lower_limit="3.7" upper_limit="6.0"/>
                    <measurement group_id="O4" value="3.7" lower_limit="2.9" upper_limit="4.8"/>
                    <measurement group_id="O5" value="4.4" lower_limit="3.5" upper_limit="5.4"/>
                    <measurement group_id="O6" value="5.0" lower_limit="4.0" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="6.7" upper_limit="11.9"/>
                    <measurement group_id="O2" value="7.2" lower_limit="5.6" upper_limit="9.3"/>
                    <measurement group_id="O3" value="9.7" lower_limit="7.2" upper_limit="13.1"/>
                    <measurement group_id="O4" value="8.5" lower_limit="6.2" upper_limit="11.7"/>
                    <measurement group_id="O5" value="9.9" lower_limit="7.3" upper_limit="13.5"/>
                    <measurement group_id="O6" value="10.6" lower_limit="7.9" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08 Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="5.2" upper_limit="8.6"/>
                    <measurement group_id="O2" value="5.7" lower_limit="4.5" upper_limit="7.1"/>
                    <measurement group_id="O3" value="5.5" lower_limit="4.3" upper_limit="6.9"/>
                    <measurement group_id="O4" value="6.8" lower_limit="5.3" upper_limit="8.6"/>
                    <measurement group_id="O5" value="6.9" lower_limit="5.4" upper_limit="8.7"/>
                    <measurement group_id="O6" value="6.4" lower_limit="5.0" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.</title>
        <description>Titers were expressed as geometric mean titers (GMTs).
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
        <time_frame>On Days 0, 21 and 63 for the first 4 groups and on Days 0, 42 and 63 for the Unadjuvanted Arepanrix/placebo/Flulaval and Arepanrix/placebo/Flulaval Groups</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.</title>
          <description>Titers were expressed as geometric mean titers (GMTs).
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) who received 2 doses and for whom assay results were available for antibodies against H1N1 antigen 21 days after the 2nd vaccine dose.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="91"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/Bri/59/07 H1N1 [at Day 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="14.1" upper_limit="21.3"/>
                    <measurement group_id="O2" value="16.7" lower_limit="13.8" upper_limit="20.2"/>
                    <measurement group_id="O3" value="18.8" lower_limit="15.2" upper_limit="23.3"/>
                    <measurement group_id="O4" value="16.2" lower_limit="12.8" upper_limit="20.6"/>
                    <measurement group_id="O5" value="14.6" lower_limit="12.0" upper_limit="17.8"/>
                    <measurement group_id="O6" value="16.6" lower_limit="13.7" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Bri/59/07 H1N1 [at Day 21 or 42]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.1" lower_limit="115.9" upper_limit="181.6"/>
                    <measurement group_id="O2" value="215.7" lower_limit="168.2" upper_limit="276.5"/>
                    <measurement group_id="O3" value="226.3" lower_limit="181.4" upper_limit="282.2"/>
                    <measurement group_id="O4" value="158.7" lower_limit="127.9" upper_limit="197.1"/>
                    <measurement group_id="O5" value="32.9" lower_limit="27.3" upper_limit="39.7"/>
                    <measurement group_id="O6" value="53.2" lower_limit="43.5" upper_limit="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Bri/59/07 H1N1 [at Day 63]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.2" lower_limit="96.5" upper_limit="149.7"/>
                    <measurement group_id="O2" value="186.5" lower_limit="150.4" upper_limit="231.4"/>
                    <measurement group_id="O3" value="157.0" lower_limit="126.0" upper_limit="195.8"/>
                    <measurement group_id="O4" value="124.3" lower_limit="99.0" upper_limit="156.1"/>
                    <measurement group_id="O5" value="137.4" lower_limit="109.0" upper_limit="173.1"/>
                    <measurement group_id="O6" value="166.9" lower_limit="132.5" upper_limit="210.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2 [at Day 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="8.1" upper_limit="12.5"/>
                    <measurement group_id="O2" value="11.8" lower_limit="9.7" upper_limit="14.4"/>
                    <measurement group_id="O3" value="8.8" lower_limit="7.4" upper_limit="10.6"/>
                    <measurement group_id="O4" value="10.2" lower_limit="8.3" upper_limit="12.6"/>
                    <measurement group_id="O5" value="10.4" lower_limit="8.4" upper_limit="12.8"/>
                    <measurement group_id="O6" value="11.5" lower_limit="9.4" upper_limit="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2 [at Day 21 or 42]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.7" lower_limit="129.6" upper_limit="238.2"/>
                    <measurement group_id="O2" value="183.5" lower_limit="135.2" upper_limit="248.9"/>
                    <measurement group_id="O3" value="181.7" lower_limit="128.1" upper_limit="257.9"/>
                    <measurement group_id="O4" value="191.4" lower_limit="138.4" upper_limit="264.7"/>
                    <measurement group_id="O5" value="12.5" lower_limit="10.0" upper_limit="15.6"/>
                    <measurement group_id="O6" value="19.1" lower_limit="15.6" upper_limit="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2 [at Day 63]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.4" lower_limit="100.4" upper_limit="179.9"/>
                    <measurement group_id="O2" value="138.4" lower_limit="104.8" upper_limit="182.7"/>
                    <measurement group_id="O3" value="132.0" lower_limit="94.9" upper_limit="183.7"/>
                    <measurement group_id="O4" value="145.6" lower_limit="107.7" upper_limit="196.8"/>
                    <measurement group_id="O5" value="216.1" lower_limit="160.0" upper_limit="292.0"/>
                    <measurement group_id="O6" value="221.9" lower_limit="167.2" upper_limit="294.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08 [at Day 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" lower_limit="41.8" upper_limit="66.3"/>
                    <measurement group_id="O2" value="47.3" lower_limit="38.0" upper_limit="58.9"/>
                    <measurement group_id="O3" value="45.4" lower_limit="36.0" upper_limit="57.4"/>
                    <measurement group_id="O4" value="40.1" lower_limit="31.5" upper_limit="51.1"/>
                    <measurement group_id="O5" value="56.7" lower_limit="45.7" upper_limit="70.5"/>
                    <measurement group_id="O6" value="58.0" lower_limit="47.2" upper_limit="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08 [at Day 21 or 42]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="662.1" lower_limit="545.4" upper_limit="803.8"/>
                    <measurement group_id="O2" value="658.3" lower_limit="540.2" upper_limit="802.0"/>
                    <measurement group_id="O3" value="478.8" lower_limit="389.5" upper_limit="588.6"/>
                    <measurement group_id="O4" value="576.1" lower_limit="479.8" upper_limit="691.8"/>
                    <measurement group_id="O5" value="74.7" lower_limit="61.4" upper_limit="90.9"/>
                    <measurement group_id="O6" value="139.5" lower_limit="120.0" upper_limit="162.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08 [at Day 63]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="506.7" lower_limit="422.3" upper_limit="608.0"/>
                    <measurement group_id="O2" value="471.2" lower_limit="396.3" upper_limit="560.2"/>
                    <measurement group_id="O3" value="359.6" lower_limit="299.4" upper_limit="431.9"/>
                    <measurement group_id="O4" value="433.5" lower_limit="369.5" upper_limit="508.7"/>
                    <measurement group_id="O5" value="644.9" lower_limit="534.5" upper_limit="778.2"/>
                    <measurement group_id="O6" value="688.1" lower_limit="593.0" upper_limit="798.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.</title>
        <description>Titers were expressed as geometric mean titers (GMTs).
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
        <time_frame>At Day 182 after dose 1 vaccination</time_frame>
        <population>The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at Day 182.</population>
        <group_list>
          <group group_id="O1">
            <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Flulaval/Placebo/Arepanrix Group</title>
            <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Flulaval/Arepanrix/Placebo Group</title>
            <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Arepanrix/Placebo/Flulaval Group</title>
            <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Antibody Titers (GMTs) for Hemagglutination Inhibition (HI) Antibodies Against Flulaval Vaccine Strains.</title>
          <description>Titers were expressed as geometric mean titers (GMTs).
Flulaval vaccines strains were A/Brisbane/59/2007 H1N1, A/Uruguay/716/2007 H3N2 and B/Brisbane/60/2008.</description>
          <population>The According-To-Protocol (ATP) cohort for immunogenicity at Day 182 included evaluable subjects (i.e. those meeting eligibility criteria, with no elimination criteria) for whom 1 dose of Flulaval vaccine and 2 doses of pandemic vaccine were administered and results were available for antibodies against H1N1 antigen at Day 182.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="89"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu A/Bri/59/07 H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.5" lower_limit="53.6" upper_limit="87.4"/>
                    <measurement group_id="O2" value="89.2" lower_limit="71.0" upper_limit="112.0"/>
                    <measurement group_id="O3" value="87.4" lower_limit="68.5" upper_limit="111.5"/>
                    <measurement group_id="O4" value="64.6" lower_limit="51.4" upper_limit="81.1"/>
                    <measurement group_id="O5" value="64.6" lower_limit="51.4" upper_limit="81.1"/>
                    <measurement group_id="O6" value="83.7" lower_limit="66.0" upper_limit="106.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu A/Uru/716/07 H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="65.8" upper_limit="121.8"/>
                    <measurement group_id="O2" value="87.7" lower_limit="64.0" upper_limit="120.3"/>
                    <measurement group_id="O3" value="87.1" lower_limit="61.4" upper_limit="123.5"/>
                    <measurement group_id="O4" value="87.8" lower_limit="63.4" upper_limit="121.4"/>
                    <measurement group_id="O5" value="110.0" lower_limit="79.3" upper_limit="152.6"/>
                    <measurement group_id="O6" value="127.2" lower_limit="92.3" upper_limit="175.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu B/Bri/60/08 Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339.9" lower_limit="276.7" upper_limit="417.5"/>
                    <measurement group_id="O2" value="273.8" lower_limit="228.7" upper_limit="327.9"/>
                    <measurement group_id="O3" value="245.4" lower_limit="197.8" upper_limit="304.3"/>
                    <measurement group_id="O4" value="292.6" lower_limit="247.0" upper_limit="346.7"/>
                    <measurement group_id="O5" value="369.6" lower_limit="300.0" upper_limit="455.3"/>
                    <measurement group_id="O6" value="378.4" lower_limit="323.4" upper_limit="442.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs:during the entire study period (Days 0-329). Unsolicited AEs: within the 84-day (Days 0-83) post-vaccination period. Solicited symptoms: During a 7-day follow-up period (Days 0-6) after vaccination</time_frame>
      <desc>SAEs were collected up to Day 329 which corresponds to the last contact day with the subjects reporting serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Flulaval/Placebo/Unadjuvanted Arepanrix Group</title>
          <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>Flulaval/Placebo/Arepanrix Group</title>
          <description>subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>Flulaval/Unadjuvanted Arepanrix/Placebo Group</title>
          <description>subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="E4">
          <title>Flulaval/Arepanrix/Placebo Group</title>
          <description>subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="E5">
          <title>Unadjuvanted Arepanrix/Placebo/Flulaval Group</title>
          <description>subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
        <group group_id="E6">
          <title>Arepanrix/Placebo/Flulaval Group</title>
          <description>subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Seminoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Gestational hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="94" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="69" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="95" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="94" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="69" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="95" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="56" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="54" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Joint pain at other location</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="54" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Temperature</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

